On August 10, 2023, ALPHA TEKNOVA ($NASDAQ:TKNO) reported its second quarter FY2023 earnings results, showing total revenue of USD 11.5 million, a 1.4% decrease year-over-year. Additionally, net income for the quarter was USD -7.2 million, a slight improvement from -6.2 million in Q2 FY2022.
Analysis – Alpha Teknova Intrinsic Value Calculator
GoodWhale has conducted an analysis of ALPHA TEKNOVA‘s wellbeing and determined that the fair value of ALPHA TEKNOVA share is around $10.6. This value was determined by GoodWhale’s proprietary Valuation Line, which factors in various variables to calculate a company’s fair market value. At the moment, ALPHA TEKNOVA stock is trading at $2.8, which is significantly undervalued by 73.6%. This presents an opportunity for savvy investors to purchase the stock at a discounted rate. Furthermore, the current situation also indicates that ALPHAT TEKNOVA’s stock may be set to increase in value as the company continues to make positive strides. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Alpha Teknova. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Alpha Teknova. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Alpha Teknova. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Alpha Teknova are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The company’s main competitors are Sunshine Biopharma Inc, SCYNEXIS Inc, and Antisense Therapeutics Ltd. All three companies are engaged in the development of new and innovative treatments for various diseases and disorders.
– Sunshine Biopharma Inc ($NASDAQ:SBFM)
Sunshine Biopharma Inc. is a pharmaceutical company that focuses on the development and commercialization of cancer and anti-infective drugs. The company’s market cap is $17.09 million and its ROE is -3.82%. Sunshine Biopharma’s products in development include Adva-27a, a treatment for ovarian and other types of cancer; and Amiket, a treatment for ketamine addiction.
SCYNEXIS Inc is a biopharmaceutical company that focuses on the development and commercialization of novel anti-infectives to address unmet needs in the treatment of serious and life-threatening infections. The company’s lead product, SCY-078, is a novel oral and intravenous (IV) antifungal agent in Phase 3 clinical development for the treatment of vulvovaginal candidiasis (VVC), also known as yeast infection, and invasive fungal infections, such as candidemia and other serious fungal infections.
– Antisense Therapeutics Ltd ($ASX:ANP)
Antisense Therapeutics Ltd is a pharmaceutical company that develops drugs to treat cancer and other diseases. The company has a market capitalization of $66.88 million and a return on equity of -21.12%. Antisense Therapeutics Ltd develops drugs that target the genetic causes of disease. The company’s drugs are designed to silence disease-causing genes. Antisense Therapeutics Ltd’s products are in clinical trials for the treatment of cancer, Huntington’s disease, and amyotrophic lateral sclerosis.
Alpha Teknova’s second quarter FY2023 earnings report showed total revenue of USD 11.5 million, a decrease of 1.4% compared to the same quarter the previous year, and a net income of -7.2 million which was an improvement from -6.2 million the previous year. Despite the slight revenue decline, the stock price was positively affected by the improved net income, moving up the same day as the report was released. Investors should take into account this information when considering Alpha Teknova as a potential investment, paying particular attention to the company’s ability to maintain a positive net income despite declining revenues and how this might influence the future of the stock.